Research and Practice in Thrombosis and Haemostasis
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Illustrated State-of-the-Art Capsules of the ISTH 2023 Congress
2023
-
Safety and efficacy of direct oral anticoagulants in chronic kidney disease: a meta-analysis..
8:102584.
2024
-
How to undertake procedures while on antiplatelet agents: a hematologist's view..
8:102539.
2024
-
Human platelets contain a pool of free zinc in dense granules.
8:102352-102352.
2024
-
Nonacog beta pegol prophylaxis in children with hemophilia B: safety, efficacy, and neurodevelopmental outcomes for up to 8 years.
8:102341-102341.
2024
-
Apixaban overdose in children: case report and proposed management. A brief communication from the Pediatric and Neonatal Thrombosis and Hemostasis SSC of ISTH.
8:102312-102312.
2024
-
Deep vein thrombosis testing in pregnancy: where is the evidence? Commentary on “Use of single whole-leg ultrasound to exclude suspected deep vein thrombosis in pregnant patients”.
8:102283-102283.
2024
-
Primary prevention of venous thromboembolism for cancer patients in randomized controlled trials: a bibliographical analysis of funding and trial characteristics.
8:102315-102315.
2024
-
Inhibitor development according to concentrate in severe hemophilia: reporting on 1392 Previously Untreated Patients from Europe and Canada.
7:102265-102265.
2023
-
The World Federation of Hemophilia World Bleeding Disorders Registry: insights from the first 10,000 patients.
7:102264-102264.
2023
-
A new approach to antiphospholipid antibody syndrome.
7:102226-102226.
2023
-
Inhibitors in hemophilia: association with surgery plans and outcomes in a retrospective cohort study.
7:102228-102228.
2023
-
OC 06.5 Use of Emicizumab for the Treatment of Acquired Hemophilia A: A Systematic Review.
7:100462.
2023
-
OC 11.1 Development and Validation of a Clinical Prediction Model for the Diagnostic Management of Acute Pulmonary Embolism: An Individual Participant Data Meta-Analysis.
7:100631-100631.
2023
-
OC 16.1 The Role of Endothelial Glycogen Synthase Kinase (GSK)-3α in Hyperglycemia-Induced Endothelial Activation and Atherosclerosis.
7:100298-100298.
2023
-
OC 20.5 The WFH Gene Therapy Registry: A Collaborative Approach Towards a Global Resource for the Long-Term Follow-up of People with Hemophilia Treated with Gene Therapy.
7:100445.
2023
-
OC 21.2 Safety of DOACs in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
7:100661-100661.
2023
-
OC 24.1 Effect of the Type of F9 Mutation on the Pharmacokinetic Profile of Patients with Hemophilia B Treated with Extended Half-Life FIX Concentrates.
7:100443.
2023
-
OC 24.2 Estimated Factor VIII Activity Levels at the Time of Bleeding Events in Individuals with Hemophilia a Without Inhibitors.
7:100436.
2023
-
OC 24.4 Effect of F8 Mutations and Von Willebrand Factor on Pharmacokinetics of FVIII Concentrates in Severe Hemophilia A.
7:100438.
2023
-
OC 40.5 Risk of All-Cause Mortality Following Anticoagulant Cessation for Unprovoked Venous Thromboembolism: A Systematic Review and Meta-Analysis.
7:100659.
2023
-
OC 54.3 Direct Oral Anticoagulants vs Low Molecular Weight Heparin in the Management of Patients with Primary or Metastatic Brain Tumours: A Systematic Review and Meta-Analysis.
7:100594-100594.
2023
-
PB0175 Impact of Reagent on the Estimation of Eloctate and Adynovate Pharmacokinetic (PK) Parameters?.
7:101061.
2023
-
PB0191 myGTR: A Patient Engagement Tool from the World Federation of Hemophilia Gene Therapy Registry.
7:101212.
2023
-
PB0299 Surface Modification of Lung Assist Device for Neonates by Dual-Modification with Antithrombin-Heparin (ATH) and Tissue Plasminogen Activator (t-PA).
7:101416-101416.
2023
-
PB0343 Longitudinal Study on the Persistence of Anti-Platelet Factor 4 Antibodies in Vaccine-Induced Immune Thrombotic Thrombocytopenia after 14 Months.
7:101485-101485.
2023
-
PB0350 Prospective Study to Evaluate the Consolidated Performance of Two Automated Rapid Assays for the Diagnosis of Heparin-Induced Thrombocytopenia.
7:101480-101480.
2023
-
PB0485 Use of DOACs in the Management of Upper Extremity Deep Venous Thrombosis: A Systematic Review.
7:101900-101900.
2023
-
PB0486 Effect of Age on Risk for Recurrent Venous Thromboembolism: A Systematic Review and Meta-Analysis.
7:101894.
2023
-
PB0593 Extending the Circulatory Half-Life of an Engineered Kallikrein-Specific Inhibitor.
7:100785-100785.
2023
-
PB0644 Evaluation of the Burden of Bone Fractures in People Living with Hemophilia: A Registry-Based Case-Control Study.
7:101184.
2023
-
PB0661 Real-World Effectiveness and Safety of Damoctocog Alfa Pegol in Canadian Patients with Hemophilia A: Interim Results from the HEM-POWR Study.
7:101178.
2023
-
PB0827 WFH World Bleeding Disorders Registry Launches the First Global Data Collection on People with von Willebrand Disease.
7:101579.
2023
-
PB0837 Analysis of the Change in Diagnosis of von Willebrand Disease by Region and Economic Status.
7:101562.
2023
-
PB1214 Characterization of Dynamic Changes to Fibrinolysis in Porcine Model of Cardiac Arrest.
7:101030.
2023
-
PB1392 Late Diagnosis of Two Adult Siblings with Bernard Soulier Syndrome (BSS).
7:101516.
2023
-
PB1426 Studies of Streptozotocin-Induced Hyperglycemia on the Host Response to Sepsis.
7:101693-101693.
2023
-
PB1478 Attributes of Randomized Controlled Trials and Their Associations with Funding Sources in Venous Thromboembolism Prophylaxis for Patients with Cancer: A Bibliographical Analysis.
7:101863-101863.
2023
-
Drug-drug interactions between direct oral anticoagulants and anticonvulsants and clinical outcomes: A systematic review.
7:100137-100137.
2023
-
Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomes.
7:100106-100106.
2023
-
Convalescent plasma therapy for coronavirus disease 2019 in ambulatory versus hospitalized patients: Efficacy and risk of thromboembolism.
7:100068-100068.
2023
-
Four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-associated bleeding: a meta-analysis of fixed versus variable dosing.
7:100107-100107.
2023
-
Proceedings of the immune thrombocytopenia summit: new concepts in mechanisms, diagnosis, and management.
7:100097-100097.
2023
-
Prevalence of selected bleeding and thrombotic events in persons with hemophilia versus the general population: A scoping review.
7:100007-100007.
2023
-
The upper extremity postthrombotic syndrome score: an international Delphi consensus study to determine the score’s functional disability component.
7:100051-100051.
2023
-
A systematic review of biomarkers among hospitalized patients with COVID‐19 predictive of venous thromboembolism: A communication from the Predictive and Diagnostic Variables Scientific and Standardization Committee of the ISTH.
6:e12786-e12786.
2022
-
Illustrated State‐of‐the‐Art Capsules of the ISTH 2022 Congress.
6:e12747-e12747.
2022
-
Prophylactic fresh frozen plasma versus prothrombin complex concentrate for preprocedural management of the coagulopathy of liver disease: A systematic review.
6:e12724-e12724.
2022
-
Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real‐world, multicenter, retrospective study.
6:e12661-e12661.
2022
-
Carbamazepine, phenytoin, and oral anticoagulants: Drug‐drug interaction and clinical events in a retrospective cohort.
6:e12650-e12650.
2022
-
Do physicians contribute to psychological distress after venous thrombosis?.
6:e12651-e12651.
2022
-
External qualification of the Web‐Accessible Population Pharmacokinetic Service–Hemophilia (WAPPS‐Hemo) models for octocog alfa using real patient data.
5:e12599-e12599.
2021
-
Magnetic resonance imaging in boys with severe hemophilia A: Serial and end‐of‐study findings from the Canadian Hemophilia Primary Prophylaxis Study.
5:e12565-e12565.
2021
-
The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B.
5:e12601-e12601.
2021
-
Vaccine‐induced immune thrombotic thrombocytopenia presenting with normal platelet count.
5:e12596-e12596.
2021
-
Global reporting of pulmonary embolism–related deaths in the World Health Organization mortality database: Vital registration data from 123 countries.
5:e12520-e12520.
2021
-
Illustrated State‐of‐the‐Art Capsules of the ISTH 2021 Congress.
5:e12532-e12532.
2021
-
Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals.
5:e12535-e12535.
2021
-
Considerations for use of direct oral anticoagulants in arterial disease.
5:e12502-e12502.
2021
-
Measuring the impact of hemophilia on families: Development of the Hemophilia Family Impact Tool (H‐FIT).
5:e12519-e12519.
2021
-
Patient‐relevant health outcomes for hemophilia care: Development of an international standard outcomes set.
5:e12488-e12488.
2021
-
Reliability of patient‐reported outcome measures: Hemorrhage, anticoagulant, antiplatelet medication use.
5:e12501-e12501.
2021
-
Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIM‐Line): A two‐center open‐label pilot randomized controlled trial.
5:e12517-e12517.
2021
-
Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA‐LEA noninterventional studies.
5:426-438.
2021
-
Updating the Canadian Hemophilia Outcomes–Kids’ Life Assessment Tool (CHO‐KLAT) in the era of extended half‐life clotting factor concentrates.
5:403-411.
2021
-
Extended half‐life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products.
5:349-355.
2021
-
Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin.
5:308-313.
2021
-
Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTE.
5:326-341.
2021
-
The psychological impact of pulmonary embolism: A mixed‐methods study.
5:301-307.
2021
-
A physician survey of perioperative neuraxial anesthesia management in patients on a direct oral anticoagulant.
5:159-167.
2021
-
Establishing diagnostic criteria and treatment of subsegmental pulmonary embolism: A Delphi analysis of experts.
4:1251-1261.
2020
-
Nonacog beta pegol (N9‐GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients.
4:1101-1113.
2020
-
High‐dose IVIG plus cangrelor platelet “anesthesia” during urgent heparin‐CPB in a patient with recent SRA‐negative HIT‐thrombosis with persisting platelet‐activating antibodies.
4:1060-1064.
2020
-
Bleeding risks for uncharacterized platelet function disorders.
4:799-806.
2020
-
The Edoxaban Hokusai VTE PEDIATRICS Study: An open‐label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease.
4:886-892.
2020
-
Management of oral anticoagulants prior to emergency surgery or with major bleeding: A survey of perioperative practices in North America: Communication from the Scientific and Standardization Committees on Perioperative and Critical Care Haemostasis and Thrombosis of the International Society on Thrombosis and Haemostasis.
4:562-568.
2020
-
The contact activation system as a potential therapeutic target in patients with COVID‐19.
4:500-505.
2020
-
Hemophilia prophylaxis adherence and bleeding using a tailored, frequency‐escalated approach: The Canadian Hemophilia Primary Prophylaxis Study.
4:318-325.
2020
-
Pharmacokinetic‐tailored approach to hemophilia prophylaxis: Medical decision making and outcomes.
4:326-333.
2020
-
Perioperative interruption of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: A comparative analysis.
4:131-140.
2020
-
Corrigendum.
3:771-771.
2019
-
Needs and challenges among physicians and researchers in thrombosis and hemostasis: Results from an international study.
3:626-638.
2019
-
Illustrated State‐of‐the‐Art Capsules of the ISTH 2019 Congress in Melbourne, Australia.
3:431-497.
2019
-
Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review.
3:528-541.
2019
-
Hemophilia trials in the twenty‐first century: Defining patient important outcomes.
3:184-192.
2019
-
Prehospital fresh frozen plasma: Universal life saver or treatment in search of a target population?.
3:12-14.
2019
-
Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study.
2:684-688.
2018
-
Systematic review of fondaparinux for heparin‐induced thrombocytopenia: When there are no randomized controlled trials.
2:678-683.
2018
-
Extended anticoagulation for unprovoked venous thromboembolism.
2:529-534.
2018
-
Focusing in on use of pharmacokinetic profiles in routine hemophilia care.
2:607-614.
2018
-
Immigration, region of origin, and the epidemiology of venous thromboembolism: A population‐based study.
2:469-480.
2018
-
Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations.
2:535-548.
2018
-
Pilot trials in thrombosis: Purpose and pitfalls.
2:572-579.
2018
-
Perioperative interruption of direct oral anticoagulants in patients with atrial fibrillation: A systematic review and meta‐analysis.
2:282-290.
2018
-
Global public awareness about atrial fibrillation.
2:49-57.
2018
-
Impact of World Thrombosis Day campaign.
1:138-141.
2017
-
Research and Practice in Thrombosis and Haemostasis – a new ISTH publishing platform for the global thrombosis and hemostasis community.
1:6-8.
2017
-
The association between platelet transfusions and bleeding in critically ill patients with thrombocytopenia.
1:103-111.
2017
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)